Big data analysis of bacterial inhibitors in parallelized cellomics: a machine learning approach

Identifying chemical compounds that inhibit bacterial infection has recently gained a considerable amount of attention given the increased number of highly resistant bacteria and the serious health threat it poses around the world. With the development of automated microscopy and image analysis systems, the process of identifying novel therapeutic drugs can generate an immense amount of data - easily reaching terabytes worth of information. Despite increasing the vast amount of data that is currently generated, traditional analytical methods have not increased the overall success rate of identifying active chemical compounds that eventually become novel therapeutic drugs. Moreover, multispectral imaging has become ubiquitous in drug discovery due to its ability to provide valuable information on cellular and sub-cellular processes using florescent reagents. These reagents are often costly and toxic to cells over an extended period of time causing limitations in experimental design. Thus, there is a significant need to develop a more efficient process of identifying active chemical compounds.

This dissertation introduces novel machine learning methods based on parallelized cellomics to analyze interactions between cells, bacteria, and chemical compounds while reducing the use of fluorescent reagents. Machine learning analysis using image-based high-content screening (HCS) data is compartmentalized into three primary components: (1) \textit{Image Analytics}, (2) \textit{Phenotypic Analytics}, and (3) \textit{Compound Analytics}. A novel software analytics tool called the Insights project is also introduced. The Insights project fully incorporates distributed processing, high performance computing, and database management that can rapidly and effectively utilize and store massive amounts of data generated using HCS biological assessments (bioassays). It is ideally suited for parallelized cellomics in high dimensional space.

Results demonstrate that a parallelized cellomics approach increases the quality of a bioassay while vastly decreasing the need for control data. The reduction in control data leads to less fluorescent reagent consumption. Furthermore, a novel proposed method that uses single-cell data points is proven to identify known active chemical compounds with a high degree of accuracy, despite traditional quality control measurements indicating the bioassay to be of poor quality. This, ultimately, decreases the time and resources needed in optimizing bioassays while still accurately identifying active compounds.